Literature DB >> 23359140

On the origin and destination of cancer stem cells: a conceptual evaluation.

Anja van de Stolpe1.   

Abstract

Despite remaining uncertainties and ongoing research it is possible to draw up a model for the role of (cancer) stem cells in both the initiation and progression of cancer towards metastasis. The cancer stem cell of origin and the cancer stem cell are, despite phenotypic similarities, genotypically different entities. Given the right circumstances provided by a combination of genomic changes and biochemical and physical interactions with its microenvironment, an epithelial cancer cell may undergo a phenotypic epithelial mesenchymal transition (EMT) towards a cancer stem cell. This transition conveys upon the cell crucial stem cell-like abilities which facilitate migration into the blood circulation as an individual circulating tumor cell, survive there, and subsequently seed into organ tissue where, once more in close interaction with its microenvironment, the process of clonal self renewal may start, leading to a metastatic tumor. Both in the primary tumor as well as in the metastatic tumor, partial differentiation of the cancer stem cell progeny leads to phenotypic heterogeneity. Throughout this complex process of cancer metastasis similarities with the way stem cells function during embryonic development, including the signaling pathways that mediate these functions, are evident. Deeper insight in the EMT process, plasticity of the resulting cancer stem cells, and the role of cancer stem cells in the metastatic process is expected to lead to novel anti-metastatic cancer therapies. Emerging human in vitro cancer models in the form of "organ-on-a-chip" may contribute valuable novel research tools to achieve this aim.

Entities:  

Keywords:  Cancer stem cell Wnt signaling pathway circulating tumor evolution metastasis

Year:  2013        PMID: 23359140      PMCID: PMC3555199     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  56 in total

1.  3D tumour models: novel in vitro approaches to cancer studies.

Authors:  Agata Nyga; Umber Cheema; Marilena Loizidou
Journal:  J Cell Commun Signal       Date:  2011-04-16       Impact factor: 5.782

Review 2.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

4.  Lgr6 marks stem cells in the hair follicle that generate all cell lineages of the skin.

Authors:  Hugo J Snippert; Andrea Haegebarth; Maria Kasper; Viljar Jaks; Johan H van Es; Nick Barker; Marc van de Wetering; Maaike van den Born; Harry Begthel; Robert G Vries; Daniel E Stange; Rune Toftgård; Hans Clevers
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

5.  Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells.

Authors:  Venkata Lokesh Battula; Kurt William Evans; Brett George Hollier; Yuexi Shi; Frank C Marini; Ayyakkannu Ayyanan; Rui-Yu Wang; Cathrin Brisken; Rudy Guerra; Michael Andreeff; Sendurai A Mani
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

6.  Interactions between cancer stem cells and their niche govern metastatic colonization.

Authors:  Ilaria Malanchi; Albert Santamaria-Martínez; Evelyn Susanto; Hong Peng; Hans-Anton Lehr; Jean-Francois Delaloye; Joerg Huelsken
Journal:  Nature       Date:  2011-12-07       Impact factor: 49.962

7.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.

Authors:  Keisuke Kurose; Kristie Gilley; Satoshi Matsumoto; Peter H Watson; Xiao-Ping Zhou; Charis Eng
Journal:  Nat Genet       Date:  2002-10-15       Impact factor: 38.330

8.  Clonal analysis of human colorectal tumors.

Authors:  E R Fearon; S R Hamilton; B Vogelstein
Journal:  Science       Date:  1987-10-09       Impact factor: 47.728

9.  Tumor self-seeding by circulating cancer cells.

Authors:  Mi-Young Kim; Thordur Oskarsson; Swarnali Acharyya; Don X Nguyen; Xiang H-F Zhang; Larry Norton; Joan Massagué
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

10.  Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.

Authors:  Arnout G Schepers; Hugo J Snippert; Daniel E Stange; Maaike van den Born; Johan H van Es; Marc van de Wetering; Hans Clevers
Journal:  Science       Date:  2012-08-01       Impact factor: 47.728

View more
  12 in total

1.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Authors:  Laura R Saunders; Alexander J Bankovich; Wade C Anderson; Monette A Aujay; Sheila Bheddah; KristenAnn Black; Radhika Desai; Paul A Escarpe; Johannes Hampl; Amy Laysang; David Liu; Javier Lopez-Molina; Milly Milton; Albert Park; Marybeth A Pysz; Hui Shao; Brian Slingerland; Michael Torgov; Samuel A Williams; Orit Foord; Philip Howard; Jacek Jassem; Andrzej Badzio; Piotr Czapiewski; David H Harpole; Afshin Dowlati; Pierre P Massion; William D Travis; M Catherine Pietanza; J T Poirier; Charles M Rudin; Robert A Stull; Scott J Dylla
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

2.  Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-κB activity and apoptosis induction.

Authors:  Li Wang; Huijie Guo; Liuqi Yang; Lihua Dong; Caiyu Lin; Jie Zhang; Ping Lin; Xiujie Wang
Journal:  Mol Cell Biochem       Date:  2013-03-31       Impact factor: 3.396

3.  Cancer Stem Cells in Tumor Modeling: Challenges and Future Directions.

Authors:  Elvan Dogan; Asli Kisim; Gizem Bati-Ayaz; Gregory J Kubicek; Devrim Pesen-Okvur; Amir K Miri
Journal:  Adv Nanobiomed Res       Date:  2021-06-23

4.  Dynamic Interactions Between Cancer Stem Cells And Their Stromal Partners.

Authors:  Tea Soon Park; Vera S Donnenberg; Albert D Donnenberg; Elias T Zambidis; Ludovic Zimmerlin
Journal:  Curr Pathobiol Rep       Date:  2014-03-01

5.  Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer.

Authors:  Sebastian Hinz; Christian Röder; Jürgen Tepel; Alexander Hendricks; Clemens Schafmayer; Thomas Becker; Holger Kalthoff
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

6.  Circulating Tumor Cells: What Is in It for the Patient? A Vision towards the Future.

Authors:  Anja van de Stolpe; Jaap M J den Toonder
Journal:  Cancers (Basel)       Date:  2014-05-28       Impact factor: 6.639

7.  Cancer Stem Cells: Plasticity Works against Therapy.

Authors:  T V Vinogradova; I P Chernov; G S Monastyrskaya; L G Kondratyeva; E D Sverdlov
Journal:  Acta Naturae       Date:  2015 Oct-Dec       Impact factor: 1.845

8.  Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women.

Authors:  Sumie Kato; Lorena Abarzua-Catalan; César Trigo; Ana Delpiano; Cristobal Sanhueza; Karen García; Carolina Ibañez; Katherine Hormazábal; Daniela Diaz; Jorge Brañes; Enrique Castellón; Erasmo Bravo; Gareth Owen; Mauricio A Cuello
Journal:  Oncotarget       Date:  2015-08-28

Review 9.  NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?

Authors:  Sten Friberg; Andreas M Nyström
Journal:  J Nanobiotechnology       Date:  2016-03-09       Impact factor: 10.435

10.  ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.

Authors:  Anieta M Sieuwerts; Márcia A Inda; Marcel Smid; Henk van Ooijen; Anja van de Stolpe; John W M Martens; Wim F J Verhaegh
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.